Spectrum Pharmaceuticals (SPPI) Announces ZEVALIN(R) and Belinostat Abstracts to Be Presented

May 23, 2011 (Business Wire) — Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced ZEVALIN^® (ibritumomab tiuxetan) and Belinostat abstracts will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 3-7, 2011 at the McCormick Place Convention Center in Chicago, Illinois.

Summary abstract are now available for viewing on the ASCO website (www.asco.org).

Friday, June 3, 2011
Time:			2:00pm to 6:00pm
Session:			Leukemia, Myelodysplasia, and Transplantation
Type:			Poster Discussion Session
Location:			McCormick Place E450b
Abstract #6521			A Phase 1 and Pharmacodynamic (PD) Study of the Histone Deacetylase (HDAC) Inhibitor Belinostat (BEL) Plus Azacitidine (AZC) in Advanced Myeloid Malignancies
Authors:			O. Odenike et al.

Saturday, June 4, 2011
Time:			8:00am to 12:00pm
Session:			Lymphoma and Plasma Cell Disorders
Type:			Poster Discussion Session
Location:			McCormick Place E450b
Abstract #8019			Use of Myeloablative Y90-Ibritumomab Tiuxetan in Patients with High-Risk CD20+ NHL Not Eligible for Standard ASCT: Five-Year Results
Authors:			L. Devizzi, et al.

Monday, June 6, 2011
Time:			1:00pm to 5:00pm
Session:			Lymphoma & Plasma Cell Disorders
Type:			General Poster Session
Location:			McCormick Place Hall A
Abstract #8048			Discriminatory Power of the 111Indium Scan (111In) in the Prediction of Altered Biodistribution of Radio-Immunoconjugate in the 90-yttrium Ibritumomab Tiuxetan Therapeutic Regimen: Meta-Analysis of Five Clinical Trials and 9 Years of Post-Approval Safety Data
Authors:			Kylstra, Jelle W. – Spectrum Pharmaceuticals, Inc.

Online Only

Abstract #e18553				Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan In Follicular Lymphoma Following Induction With Modern Chemoimmunotherapy Regimens: A Single-Institution Experience
Authors:				N.V. Koshy, et al.

Abstract #e18503			Y90 Ibritumomab Tiuxetan With Maintenance Rituximab As Initial Therapy For High Tumor Burden Follicular Lymphoma: A Wisconsin Oncology Network Study
Authors:			K. Thorhildur, et al

Abstract #e17511			Management of Thymic Epithelial Tumors (TETs) at the National Cancer Institute (NCI)
Authors:			A. Rajan, et al

About Belinostat

Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effect is thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis (programmed cell death), inhibition of angiogenesis, induction of differentiation, and the resensitization of cells that have become resistant to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors. Belinostat is the only HDAC inhibitor in clinical development with multiple potential routes of administration, including intravenous administration, continuous intravenous infusion and oral administration.

Belinostat is currently in a registrational trial, the BELIEF Study, under a Special Protocol Assessment (SPA), as a monotherapy for relapsed or refractory Peripheral T-Cell Lymphoma (PTCL), an indication for which it has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration. Belinostat is also under investigation in a randomized Phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for cancer of unknown primary (CUP). The CUP study is being run and fully funded by our partner Topotarget A/S. Additionally, the National Cancer Institute is currently conducting several clinical trials of belinostat in a variety of hematological and solid tumors, both as monotherapy as well as combination therapy.

About ZEVALIN^® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan), injection for intravenous use is indicated for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy. ZEVALIN is also indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma.

ZEVALIN is a CD20-directed radiotherapeutic antibody. The ZEVALIN therapeutic regimen consists of three components: rituximab, Indium-111 (In-111) radiolabeled ZEVALIN for imaging, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. The ZEVALIN therapeutic regimen is a form of cancer therapy called radioimmunotherapy. Radioimmunotherapy (RIT) is an innovative form of cancer treatment with a mechanism of action that is different from traditional chemotherapy. RIT builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope.

Important ZEVALIN^® Safety Information

Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the ZEVALIN therapeutic regimen.

Please see full Prescribing Information, including Boxed WARNINGS, for ZEVALIN and rituximab. Full prescribing information can be found at www.ZEVALIN.com.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.

Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum’s ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company’s reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ^®, ZEVALIN^®, and FUSILEV^® are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

^© 2011 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Spectrum Pharmaceuticals, Inc.

Paul Arndt

Senior Manager, Investor Relations

702-835-6300